Burkina Faso
Tuberculosis profile
| High HIV burden |
Population  2013 17 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (0.96–2) 8.9 (5.7–12)
Mortality (HIV+TB only) 0.33 (0.26–0.41) 2 (1.5–2.4)
Prevalence  (includes HIV+TB) 14 (7.2–22) 80 (43–128)
Incidence  (includes HIV+TB) 9.1 (8.3–10) 54 (49–60)
Incidence (HIV+TB only) 1.1 (1–1.3) 6.8 (6.2–7.5)
Case detection, all forms (%) 59 (53–64)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
85 (5–240) 80 (0–160)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 616   208
Pulmonary, clinically diagnosed 865   0
Extrapulmonary 637   0
       
Total new and relapse 5 326    
Previously treated, excluding relapses 194    
Total cases notified 5 520    
Among 3 616 new cases:
54 (1%) cases aged under 15 years; male:female ratio: 2.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 (<1%) 156 (39%) 175
Laboratory-confirmed RR-/MDR-TB cases     59
Patients started on MDR-TB treatment     41
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 295 (96)
HIV-positive TB patients 668 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 655 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 655 (98)
HIV-positive people screened for TB 40 558  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 80
Previously treated cases registered in 2012 74
HIV-positive TB cases, all types, registered in 2012 76
RR-/MDR-TB cases started on second-line treatment in 2011 73
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0.9
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 4 058
% Funded domestically <1%
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-03 Data: www.who.int/tb/data